Get startedLog in
    Picture of Maxigen Biotech logo

    1783 — Maxigen Biotech Cashflow Statement

    0.000.00%
    tw flag iconLast trade - 00:00
    Consumer DefensivesBalancedSmall CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Maxigen Biotech, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line76.797.5166193226
    Depreciation
    Amortisation
    Non-Cash Items-0.6225.1913.8-30.7-6.27
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital-34.9-1859.2-18.851.9
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Other Assets
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities74.4118268171298
    Capital Expenditures-11.3-15.4-12-19-31.8
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items15012.722.4-4712.7
    Sale of Fixed Assets
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities139-2.7710.4-490-29.1
    Financing Cash Flow Items-2150.101-0.10100.542
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-271189-1.05-41.4-59.7
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-57.9304278-360208